Association of Gene Variants of Plasmic (FGB -455 G>A (rs1800790), F2 20210 G>A (rs1799963), F5 1691 G>A (rs6025), F7 10976 G>A (rs6046), F13 G>T (rs5985)), Thrombocytic (ITGA2 807 C>T (rs1126643), ITGB3 1565 T>C (rs5918)), Fibrinolytic (PAI-1 -675 5G>4G (rs1799889)) Hemostasis Components with Arterial or Venous Thrombosis in Newborns: Case-Controlled Study

Background. The severity of thrombosis clinical course, poor prognosis, upcoming disability and permanent organ failure in newborns necessitate further search and study of thrombotic conditions predictors in order to prevent them. Aim of the study is to analyze the frequency of gene variants of plasmic, thrombocytic and fibrinolytic hemostasis components and determine their role in the thrombosis development in newborn children. Methods. The study included 46 full-term newborns with thromboses of different localization – cases group. Inclusion criteria were: child age 28 days or less, gestational period >37 weeks, informed consent on participation in the study. The control group included children of I and II health groups. Vascular thrombosis was diagnosed via instrumental imaging methods: vascular ultrasound, computer tomography, magnetic resonance imaging. Thrombophilic anamnesis and pregnant woman’s health condition was analyzed according to pregnancy medical records. The molecular genetic testing included 8 single nucleotide polymorphisms definition of the following genes: FGB -455 G>A (rs1800790), F2 20210 G>A (rs1799963), F5 1691 G>A (rs6025), F7 10976 G>A (rs6046), F13 G>T (rs5985), ITGA2 807 C>T (rs1126643), ITGB3 1565 T>C (rs5918), PAI-1 -675 5G>4G (rs1799889). Results. Molecular genetic predictors of thrombosis in newborns have been revealed: variants of fibrinogen gene FGB -455 G>А (AP, %=66), plasminogen activator inhibitor gene PAI-1 -675 4G > 4G (AP, % = 89), genotype associations PAI-1 -675 4G/>4G /F7 10976 G>G (AP, % = 82), PAI-1 -675 4G>4G / F13 34 G>G (AP, % = 63)PAI-1 -675 4G>4G / F7 10976 G>G / F13 34 G>G(AP, % = 61), and integrin alpha 2 gene ITGA2 807 T/T (AP, % = 93). Maternal factor of thrombosis development in children is impaired uteroplacental circulation in pregnant woman (AP, % = 66). Conclusion. The role of gene variants of plasmic, thrombocytic and fibrinolytic hemostasis components in development of thrombosis in newborns was determined, as well as quantitative estimation of their contribution was presented.

1. Van Ommen CH, Heijboer H, Buller HR, et al. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands. J Pediatr. 2001;139(5):676–681. doi: 10.1067/mpd.2001.118192.

2. Lee ACW, Li CH, Szeto SC, Ma ESK. Symptomatic venous thromboembolism in Hong Kong Chinese Children. Hong Kong Med J. 2003;9(4):259–262.

3. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000;47(6):763–766. doi: 10.1203/00006450-200006000-00013.

4. Williams AN. Childhood stroke — beyond re-inventing the wheel. Eur J Paediatr Neurol. 2000;4(3):103–107. doi: 10.1053/ejpn.2000.0276.

5. Nowak-Gottl U, Duering C, Kempf-Bielack B, Strater R. Thromboembolic diseases in neonates and children. Pathophysiol Haemost Thromb. 2003/2004;33(5–6):269–274.

6. Raffini L, Huang YS, Witmer C, Feudtner C. Dramatic increase in venous thromboembolism in children’s hospitals in the United States from 2001 to 2007. Pediatrics. 2009;124(4):1001–1008. doi: 10.1542/peds.2009-0768.

7. Setty B, O’Brien SH, Kerlin BA. Pediatric venous thromboembolism in the United States: a tertiary care complication of chronic diseases. Pediatr Blood Cancer. 2012;59(2):258–264. doi: 10.1002/pbc.23388.

8. Svirin PV, Rumyantsev SA, Larina LE, et al. Neonatal thrombosis: treatment regimen. Neonatology: News, Opinions, Training. 2013;(1):76–84. (In Russ).

9. Makatsariya AD, Bitsadze VO, Khizroeva DKh, et al. Thromboprophylaxis in pregnant women with thrombophilia and thrombosis in anamnesis. The Bulletin of Siberian Branch of Russian Academy of Medical Sciences. 2013;33(6):99–109. (InRuss).

10. Girolami A, Cosi E, Ferrari S, Girolami B. Prothrombin: Another Clotting Factor After FV That Is Involved Both in Bleeding and Thrombosis. Clin Appl Thromb Hemost. 2018;24(6):845–849. doi: 10.1177/1076029618770741.

11. , , . Lack of Associations Between PAI-1 and FXIII Polymorphisms and Arterial Ischemic Stroke in Children: A Systematic Review and MetaAnalysis. Clin Appl Thromb Hemost. 2019;25:1076029619869500. doi: 10.1177/1076029619869500.

12. Kenet G, Lütkhoff LK, Albisetti M, et al. Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children A Systematic Review and Meta-Analysis of Observational Studies. Circulation. 2010;121:1838–1847.

13. Jzenberg N, Berroeta C, Philip I, et al. Association of the -92C/G and 807C/T polymorphisms of the alpha2 subunit gene with human platelets alpha2beta1 receptor density. Arterioscler Thromb Vasc Biol. 2005;25(8):1756–1760. doi: 10.1161/01.ATV.0000173308.13054.4f.

14. Rumyantsev AG, Maschan AA, Zharkov PA, Svirin PV. Federal’nye klinicheskie rekomendatsii po diagnostike, profilaktike i lecheniyu trombozov u detei i podrostkov. Moscow; 2015. 113 p. (In Russ). Доступно по: https://nodgo.org/sites/default/files/34.%20%D0%A2%D1%80%D0%BE%D0%BC%D0%B1%D0%BE%D0%B7%D1%8B.pdf. Ссылка активна на 10.11.2020.

15. Appropriateness Criteria. In: American College of Radiology ACR. Clinical Resources. Available online: https://www.acr.org/ClinicalResources/ACR-Appropriateness-Criteria. Accessed on November 10, 2020.

16. Kel’manson I.A. Printsipy dokazatel’noi pediatrii. St. Petersburg: Foliant; 2004. — 240 p. (In Russ).

17. Geneticheskii pasport kak osnova individual’noi i prediktivnoi meditsiny. Baranov VS, ed. St. Petersburg: “Izdatel’stvo N-L”; 2009. 528 p. (In Russ).